NeoGenomics, Inc. is a cancer diagnostics company specializing in cancer genetics testing and information services. The Company offers comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with diagnostic and predictive testing to help them diagnose and treat cancer. Its services include clinical cancer testing; interpretation and consultative services; molecular and NGS testing; comprehensive technical and professional services offering; clinical trials and research; validation laboratory services, and oncology data solutions. It operates a network of laboratories for full-service sample processing and analysis services throughout the United States and a full-service sample-processing laboratory in Cambridge, United Kingdom. Its testing services include Cytogenetics (karyotype analysis), Fluorescence In-Situ Hybridization (FISH), Flow cytometry, and others.
Unternehmens-codeNEO
Name des UnternehmensNeogenomics Inc
IPO-datumDec 10, 2012
Gegründet am1998
CEOMr. Antony P. Zook
Anzahl der mitarbeiter2200
WertpapierartOrdinary Share
GeschäftsjahresendeDec 10
Addresse9490 Neogenomics Way
StadtFORT MYERS
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl33912
Telefon12397680600
Websitehttps://neogenomics.com/
Unternehmens-codeNEO
IPO-datumDec 10, 2012
Gegründet am1998
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten